What's happening?

news4

Published September 23, 2013

XSpray CEO explains the HyNap platform for PKIs

XSpray’s proprietary HyNap™ formulation technology has consistently shown major improvements in solubility and improved bioavailability for all to date tested small molecule protein kinase inhibitors. This is a surprising achievement considering that such compatibility with a whole class of compounds are very rare for any drug delivery technology. In this early video, Per Andersson XSpray CEO, explains the concept.  See video »